Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
about
Nicotine receptor partial agonists for smoking cessationNicotine receptor partial agonists for smoking cessationPharmacological interventions for smoking cessation: an overview and network meta-analysisCardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort studyNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database.Optimizing Clinical Trial Enrollment Methods Through "Goal Programming"Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study.Current and emerging pharmacotherapeutic options for smoking cessation.Does smoking cessation with varenicline worsen vascular endothelial function?Drug safety assessment in clinical trials: methodological challenges and opportunitiesSafety of varenicline in patients with cardiovascular disease.Cardiovascular adverse events associated with smoking-cessation pharmacotherapies.Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme.Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells.Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study).Varenicline-induced coronary thrombosis.
P2860
Q24185773-D0D6F992-14B4-4C69-A636-43A77B472403Q24200322-8CC8ABA5-9BC7-46A8-BCC2-3E7F872AA5A9Q24202961-FCD4566E-E7B9-4936-A7C9-6872B3051F0CQ28267175-4749F392-B99E-4B5F-9213-96B26D1EED2FQ28277165-E3EE2548-0F4E-4DDD-B1E4-E2659222285CQ34144971-65C2A86B-E1DA-4CB6-B28E-E6D7FF35213DQ35026628-F36A6721-4621-40DD-87D5-975870618839Q36384815-E3CA5005-53D2-4835-A2EE-28CB680084A4Q36891273-F27E1A9B-EAB9-474A-BF38-771D70775E1AQ36956697-E69A47CF-03DF-48AC-A3F8-FBAD1C7EDD22Q38035953-342F301F-7EDC-4834-99AC-236DC95EB46CQ38147825-4DB16CEE-3854-4247-9B79-4E4AD9774465Q38269624-82E87D16-8F8F-4BF7-9C7B-98F400F884AFQ44992814-E4FA23EC-1307-4819-A1A0-4C1D30F4E420Q48037427-F8EA601F-CD40-4BF3-8969-142FA0DF6676Q51710237-2C4D7E74-2B39-4309-B8EA-7B838638054DQ54562053-08CB89BA-A9A4-482A-9676-973C4F83552E
P2860
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Cardiovascular events in patie ...... g surveillance in New Zealand.
@en
Cardiovascular events in patie ...... g surveillance in New Zealand.
@nl
type
label
Cardiovascular events in patie ...... g surveillance in New Zealand.
@en
Cardiovascular events in patie ...... g surveillance in New Zealand.
@nl
prefLabel
Cardiovascular events in patie ...... g surveillance in New Zealand.
@en
Cardiovascular events in patie ...... g surveillance in New Zealand.
@nl
P2093
P2860
P1433
P1476
Cardiovascular events in patie ...... g surveillance in New Zealand.
@en
P2093
Janelle Ashton
Mira Harrison-Woolrych
Ruth Savage
Simran Maggo
P2860
P356
10.2165/11597690-000000000-00000
P577
2012-01-01T00:00:00Z
P5875
P6179
1053131018